Monopar commenced a Phase 1b open-label dose escalation clinical trial in the US in Q3 2021 in advanced soft tissue sarcoma (ASTS) patients. Following completion of the Phase 1b trial, Monopar anticipates conducting a randomized, Phase 2 clinical trial evaluating camsirubicin head-to-head against doxorubicin in the 1st line treatment setting for ASTS. The primary endpoint of the trial is planned to be progression-free survival, with secondary endpoints that will include response rate and overall survival. Camsirubicin has been granted Orphan Drug Designation in both the US and EU.
Orphan Drug Designation
Learn more about the European Commission’s Orphan Drug Designation of camsirubicin for the treatment of soft tissue sarcoma